BioSpace News Archive

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced that Cancer Research Communications published positive clinical data from the dose-escalation Phase 1 trial of TPST-1120 in an article titled “First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.”

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence as an exhibitor at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

The PHERGain clinical trial, developed by MEDSIR - a company dedicated to promoting independent clinical research in oncology internationally - has been published in the prestigious journal The Lancet, following positive results showing that one-third of patients with localized HER2-positive breast cancer can be cured without requiring chemotherapy, drastically reducing side effects.

NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA.

Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox family biologics, announced a Good Manufacturing Practice- plasmid DNA contract development and manufacturing organization agreement.

Debiopharm today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

Agilent Technologies Inc. announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows.

In response to the pressing need of effective treatments for these metabolic disorders, researchers at the led by Prof. Jin Hee Ahn from Gwangju Institute of Science and Technology (GIST) meticulously developed compound 11c, a novel peripheral 5HT2A antagonist.